GlassScriptPhysician profile
Meredith Stocklin
NPI 1891414660
$7,620.42
in general payments reported to CMS, 2019-2025
29 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $581 · 2023: $3,307 · 2024: $2,076 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,020 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,020.01 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,484.86 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,377.51 | 2023-2025 | |
| Amgen INC. | $1,226.57 | 2022-2025 | Repatha, Evenity, Otezla |
| Otsuka America Pharmaceutical, INC. | $689.27 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lilly USA, LLC | $511.78 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $425.66 | 2022-2025 | Xifaxan |
| Pfizer INC. | $304.31 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $254.49 | 2023-2025 | |
| Novo Nordisk INC | $215.22 | 2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $163.43 | 2023-2025 | Capvaxive, Verquvo, Gardasil 9 |
| Alkermes, INC. | $142.04 | 2022-2024 | Vivitrol, Vivitrol |
| Madrigal Pharmaceuticals | $141.23 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $126.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $117.20 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $104.26 | 2022-2023 | Livalo, Seglentis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $84.38 | 2023 | Veozah |
| Xeris Pharmaceuticals, INC. | $30.22 | 2023 | Gvoke Hypopen |
| Tolmar, INC. | $30.06 | 2023 | |
| Vertos Medical, INC. | $27.55 | 2023 | Mild Device Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.36 | 2023 | |
| Dexcom, INC. | $19.12 | 2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $18.78 | 2024 | Inspire |
| Seqirus USA INC | $16.98 | 2022 | |
| Lundbeck LLC | $16.31 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $15.40 | 2025 | Shingrix |
| Axsome Therapeutics, INC. | $15.21 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.24 | 2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $13.96 | 2024 | Trintellix |
| Fidia Pharma USA INC. | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Stocklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.